Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II Trial.
Journal: Cancer research communications
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Briata IM, Carbone A, Foersch S, et al. (2026). "Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II Trial.". Cancer research communications. https://doi.org/10.1158/2767-9764.crc-26-0556